














httpAntithrombotic therapy after infrainguinal bypass
Mario Maufus, MD,a and Gilles Pernod, MD, PhD,a,b Grenoble, France
Objective: Bypass surgery is regularly performed for the treatment of critical limb ischemia, but the risk of occlusion
remains signiﬁcant. Antiplatelet therapy in patients with arterial disease is useful for secondary cardiovascular and bypass
occlusion prevention. However, despite the common use of an antiplatelet agent, especially aspirin, which became the
standard of care, the risk of graft occlusion persists. The best antithrombotic treatment for bypass patency therefore
remains a matter of debate.
Methods:We conducted a systematic literature search to identify studies and consensus reporting the use of antithrombotic
treatment to prevent bypass occlusion. We excluded case reports and clinical trials with a placebo arm.
Results: Aspirin remains the mainstay of treatment to improve infrainguinal bypass patency; however, the effect differs
according to the bypass material used. The greatest beneﬁcial effect of antiplatelet agents was observed with prosthetic
bypasses. In such cases, the addition of clopidogrel to aspirin, for at least 1 year, in patients who beneﬁted from a below-
knee bypass graft signiﬁcantly improved bypass patency (occlusion 32% vs 47% for aspirin alone; P [ .02) and the
amputation rate (9.4% vs 19.2% for aspirin alone; P [ .03), without increasing the incidence of major hemorrhage. In
contrast, antiplatelet regimens were less efﬁcacious for autologous vein bypasses. The addition of a vitamin K antagonist
(VKA) is not routinely proposed because of the increased incidence of associated major hemorrhage. The use of VKA
alone, instead of aspirin, should probably be discussed in selected patients, and a combination of VKA and antiplatelet
agents should be discussed in patients with venous infrainguinal bypasses considered to be at a high risk for occlusion.
Conclusions: Although aspirin remains the ﬁrst-line treatment to prevent infrainguinal bypass occlusion, future studies are
needed to deﬁne stronger recommendations. (J Vasc Surg 2014;60:1367-75.)Vascular surgery is regularly performed for the treatment
of critical limb ischemia.1 However, the risk of occlusion in
cases of infrainguinal bypass is signiﬁcant.2,3 The incidence
of bypass occlusion is about 5% to 15% per year for autolo-
gous vein bypass and 11% to 20% per year for polytetra-
ﬂuoroethylene prosthetic bypass,4 and the incidence
increases when the distal anastomosis is located below the
knee.5
Antiplatelet agents are effective in patients with periph-
eral arterial disease and are widely used to reduce cardiovas-
cular events, such as myocardial infarction or ischemic
stroke, and also to reduce arterial occlusion. The Antiplate-
let Trialists’ Collaboration concluded that the use of an
antiplatelet agent was associated with a 43% (standard
deviation, 8%; P < .001) reduction of the relative risk
(RR) for bypass occlusion.6 Similar results were shown in
a Cochrane meta-analysis of antiplatelet agents compared
with placebo.7 However, despite the common use of an
antiplatelet agent, especially aspirin, the risk of graft occlu-
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://dx.doi.org/10.1016/j.jvs.2014.07.105Although aspirin remains the standard of care for all
types of bypass surgery, several antithrombotic approaches
have been evaluated for long-term treatment, including the
use of a vitamin K antagonist (VKA), dual-antiplatelet ther-
apy, or the combination of a VKA and aspirin. Data from
societal consensus have often been in disagreement because
they propose different therapeutic approaches for a same
bypass (Table I). Questions therefore remain about the
best oral long-term antithrombotic therapy to use to
improve the bypass patency rate. The aim of this review
was to analyze the available updated data on the beneﬁt
and risk of antithrombotic therapy used to improve the
bypass patency rate.METHODS
We conducted a systematic literature search of
MEDLINEandEMBASE (1990 to 2013) to identify poten-
tial studies by using the keywords antithrombotic, antiplate-
let agent, aspirin, clopidogrel, and VKA, together with
arterial bypass, infrainguinal bypass, venous or prosthetic
bypass, bypass occlusion, and bypass patency. We also
analyzed recently published consensus statements regarding
the use of antithrombotic drugs to prevent bypass occlusion.
For eachdrug,we analyzed thedesignof the study, the tested
drug, and the effect on outcome.
Study selection. All clinical trials were considered if
they were related to antithrombotic drugs to prevent
bypass occlusion. We excluded case reports and studies in
which only cardiovascular outcomes were reported.
Because the use of antiplatelet therapy was recommended
for all of these patients, we excluded clinical trials with pla-
cebo arms or pentoxifylline. We excluded reporting results
regarding low-molecular-weight heparins because these1367
Table I. Reported use of antithrombotic regimens to prevent venous or prosthetic bypass occlusion in the Cochrane
meta-analysis and consensus conferences
Organization Venous Prosthetic
Cochrane W > ASA
CASA ¼ W
ASA
ESC W > ASA? CASA
ACCP 2012 ASA or clopidogrel CASA 1y
French Health Authority ASA or clopidogrel (if high risk of occlusion, WASA) ASA (CASA?)
AACP, American College of Chest Physicians; ASA, acetylsalicylic acid; CASA, clopidogrel plus acetylsalicylic acid; ESC, European Society of Cardiology; W,
warfarin; WASA, warfarin plus acetylsalicylic acid.












Sarac,9 1998 56/64 64/0 6/58 High-risk autogenous vein
infrainguinal bypass: warfarin
(INR 2.0-3.0) þ ASA vs ASA
(325 mg/d) alone
10/14 17/5
BOA Study,10 2000 2690/2690 1546/1104 1222/1428 Warfarin (INR 3.0-4.5) vs ASA
(80 mg)
308/322 119/59
Johnson,11 2002 831/831 458/373 395/400 (36 bypass
failure off warfarin
not available)
Warfarin (INR 1.4-2.8) þ ASA




851/851 598/253 0/851 ASA (75-100 mg) and
clopidogrel (75 mg) vs ASA
(75-100 mg) and placebo
93/97 25/9
Monaco,14 2012 341/341 110/221 221/110 Warfarin INR (2.0-2.5) þ
clopidogrel (75 mg) vs ASA
(100 mg) þ clopidogrel
(75 mg)
21/30 15/13
ASA, Acetylsalicylic acid; INR, international normalized ratio.
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a high dose of aspirin (>500 mg/d) were also excluded.
Data extraction. The two reviewers independently
assessed eligibility and analyzed the identiﬁed articles. All
of the collected data were veriﬁed by each of the partici-
pating investigators. Discrepancies in data extraction were
resolved by consensus, referring back to the original article.
Outcome measures. Outcomes measures were bypass
patency, amputation, and hemorrhage.
Statistical methods. The RR or hazard ratio (HR)
were shown as originally reported when available. In their
absence, the RR and 95% conﬁdence interval (CI) was
calculated from the original data.
RESULTS
Main characteristics of analyzed clinical trials are
reported in Table II.
Infrainguinal autologous vein bypasses. A study
published in 1979 by Schneider8 comparing warfarin
with acetylsalicylic acid (ASA) showed a signiﬁcant higher
rate of patency at 24 months using warfarin (odds ratio
[OR] for occlusion, 0.38; 95% CI, 0.16-0.91). More
adverse events were reported in the ASA group (21%) than
in the warfarin group (0.6%). However, we excluded this
study because of the higher dose of ASA used at this time
(1 g/d).In 1998, Sarac et al9 evaluated the beneﬁt of long-term
anticoagulation for infrainguinal bypasses at a high risk of
occlusion. Inclusion criteria were poor-quality vein, poor
arterial runoff, or iterative bypass. Patients were allocated
to the ASA group (325 mg/d) or to a group that received
warfarin (international normalized ratio [INR] target
between 2 and 3) plus ASA (WASA; 325 mg/d). From
1991 to 1995, 56 patients with 64 bypasses were included
and monitored for 36 months.
Perioperative and 5-year survival rates were similar
in both groups. The immediate (day 5) postoperative pri-
mary graft patency rates were similar in both groups
(97.3% for WASA and 85.2% for ASA; P ¼ .07). In
contrast, limb salvage was signiﬁcantly higher in the
WASA group (100%) compared with the ASA group
(88.9%; P ¼ .04). The 3-year primary patency rate was
higher in the WASA group than in the ASA group (73%
vs 48%, P ¼ .04), as were the primary assisted patency
rate (77% vs 56%; P ¼ .05) and the secondary patency
rate (81% vs 56%; P ¼ .02). Cumulative limb salvage
rates were higher in the WASA group (81% vs 31%;
P ¼ .01; Figs 1 and 2). Major hemorrhagic complications
(intracranial, gastrointestinal and genitourinary) were 46%
in the WASA group vs 8.5% in the ASA group.
Published in 2000, the Bypass Oral Anticoagulants or
Aspirin (BOA) study10 was an open-label, multicenter
Fig 1. Efﬁcacy and tolerance of antithrombotic drugs reported for all infrainguinal bypasses. The open boxes indicate
occlusion/amputation, and the black boxes indicate hemorrhages. Patency was reported at 3 years,a 1 year,b 5 years,c
and 2 years,d as originally reported. The relative risk (RR) or hazard ratio (HR) are shown as originally reported when
available or the RR was calculated from the original data.*Occlusion was reported based on the analysis of primary and
primary assisted patency. ¤Includes death, and gastrointestinal (GI), central nervous system (CNS), and genitourinary
(GU) complications. ASA, Acetylsalicylic acid; CASA, combination of clopidogrel and acetylsalicylic acid; W, warfarin;
WASA, combination of warfarin and aspirin.
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study randomized 2690 patients from April 1995 to March
1998 to the VKA group (INR target 3 to 4.5) who under-
went 784 autologous vein bypasses and 412 prosthetic by-
passes, or the ASA group (80 mg/d), with 762 autologous
vein bypasses and 446 prosthetic bypasses. The mean
follow-up was 21 months, and the primary outcome was
bypass occlusion.
The overall occlusion rate (vein and prosthetic
bypasses) was 14% patient-years in each group (308 graft
occlusions in the VKA group and 322 in the ASA group;
Fig 1). The secondary outcome, a composite of deathdue to vascular causes, myocardial infarction, stroke, major
amputation, death from all causes, and major hemorrhage,
was similar in both groups (HR, 0.89; 95% CI, 0.75-1.06).
The rate of amputation was also similar, with 100 (7.5%) in
the VKA group and 110 (8.3%) in the ASA group. INRs
were within the target range of 3.0 to 4.5 only w50% of
the time, and 8% of patients taking oral anticoagulants
changed to aspirin. Overall, major hemorrhages, especially
intracranial hemorrhages, were more frequent in the VKA
group (4.7% per year) than in theASA group (2.5% per year).
In the subgroup analysis of the primary outcome event,
the HRs of anticoagulants compared with aspirin were
Fig 2. Efﬁcacy and tolerance of antithrombotic drugs reported for venous infrainguinal bypasses. The open boxes are for
occlusion/amputation, and the black boxes are for hemorrhages. Patency was reported at 3 years,a 1 year,b 5 years,c and
2 years,d as originally reported. The relative risk (RR) or hazard ratio (HR) are shown as originally reported when
available, or the RR was calculated from the original data.*Occlusion was reported based on the analysis of primary and
primary assisted patency. ¤Includes death and gastrointestinal (GI), central nervous system (CNS), and genitourinary
(GU) complications. ASA, Acetylsalicylic acid; CASA, combination of clopidogrel and acetylsalicylic acid; W, warfarin;
WASA, combination of warfarin and aspirin.
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bypass grafts. Interestingly, the primary outcome was bet-
ter in the VKA group than in the ASA group in those
who received autologous vein bypass (Fig 2).
Published in 2002, the Veterans Affairs Cooperative
Study was an open-label multicenter study that included
patients with elective scheduled bypasses.11 Patients were
assigned to the ASA group (325 mg/d) or to the WASA
group (ASA [325 mg/d] and warfarin [INR target 1.4-2.8]).
The primary outcome was the bypass patency rate at 5 years,
and mortality and morbidity were the secondary end points.
The study included 831 patients from October 1991 to
September 1995, with a mean follow-up of 36 months. Of
these, 373 patients had a prosthetic bypass and 458 had anautologous vein bypass. A total of 413 patients received ASA
and 418 received WASA.
Overall (vein and prosthetic bypasses), occlusion
occurred in 101 patients in the WASA group and in 123
in the ASA group (Fig 1). Myocardial infarction and stroke
analysis did not show any beneﬁt of WASA vs ASA alone.
In contrast, overall mortality was higher in the WASA
group vs the ASA group (RR, 1.41; 95% CI, 1.09-1.84;
P ¼ .01). Major hemorrhages were more frequent in the
WASA group, at 4.1% per patient/year, compared with
1.5% per patient/year in the ASA group (P ¼ .02;
Fig 1). This study reported higher lethal intracranial hem-
orrhages with long-term use of WASA (0.95% vs 0.2% in
ASA groups).
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bypasses, the 5-year patency rate was similar in both
groups. There were 57 occlusions in the ASA group
(25.1%) and 57 occlusions in the WASA group (24.7%;
Fig 2). Subset analysis for femoropopliteal above-knee,
femoropopliteal below-knee, or femorotibial/peroneal
bypasses did not show any signiﬁcant beneﬁt for warfarin.
For autologous vein bypass, 27 major hemorrhages
(11.7%) occurred in the WASA group compared with 12
(5.3%) in the ASA group (Fig 2).
Regarding patients included in the Veteran’s Affairs
study, Jackson et al12 reviewed the outcomes for tolerance
and severe ischemia according to the antithrombotic treat-
ment allocated when occlusion occurred. Among the 831
patients included, 402 had a femoropopliteal bypass, and
only patients with occluded bypasses were analyzed. The
primary end point was ischemia severity: grade I (viable),
grade II (threatening), or grade III (overtaken). Of the
406 femoropopliteal bypasses, 100 occlusions occurred in
the 36 to 39 months of follow-up. Among patients allo-
cated to WASA group, 20% of occlusions occurred while
the INR was below the target range (<1.4). Among the
169 autologous vein bypasses, 33 occluded, 10 in the
WASA group and 23 in the ASA group, showing no beneﬁt
of additional VKA treatment with ASA.
The Clopidogrel and Acetylsalicylic Acid in Bypass
Surgery for Peripheral Arterial Disease (CASPAR) study
was a randomized, prospective, double-blinded, controlled
multicenter study published in 2010 that compared the
efﬁcacy and safety of treatment with clopidogrel (75 mg/d)
plus ASA (75-100 mg/d; CASA) vs ASA (75 to 100 mg/d)
alone.13 Patients had a below-knee bypass. Patients with
VKA indications were excluded.
The study included 851 patients from September 2004
to August 2006, and 425 bypasses were allocated to the
CASA group, with 426 in the ASA group. The primary
end point was bypass occlusion, a surgical procedure con-
cerning the bypass, major amputation, or death. The sec-
ondary outcome was death from cardiovascular causes,
myocardial infarction, stroke, and major amputations.
Safety outcomes were severe hemorrhage, as deﬁned by
the Global Use of Strategies to Open Occluded Coronary
Arteries (GUSTO) study (life-threatening, intracerebral
or with hemorrhagic shock). Moderate hemorrhages (ie,
needing red cell transfusion) were also analyzed.
The overall analysis found no statistically signiﬁcant dif-
ferences for the primary and secondary efﬁcacy outcomes
between the two groups (HR, 0.98; 95% CI, 0.78-1.23;
P ¼ .87; Fig 1). Bypass patency was linked to the site of
the distal anastomosis (popliteal or tibial). Regarding autol-
ogous vein bypasses (297 assigned to CASA and 301
assigned to ASA), there was no difference in the primary ef-
ﬁcacy end point or bypass occlusion (Fig 2).
In the safety analysis, severe hemorrhage was more
frequent in the CASA group (nine patients [2.1%]) vs the
ASA group (ﬁve patients [1.2%]); nevertheless, this differ-
ence was not statistically signiﬁcant. More severe and mod-
erate hemorrhagic events occurred in the CASA group (25[5.9%]) than in the ASA group (nine [2.1%]; P < .001;
Figs 1 and 2).
In 2012, Monaco et al14 published an open-label ran-
domized prospective study that compared the efﬁcacy and
safety of treatment with dual-antiplatelet therapy with
CASA (clopidogrel [75 mg/d] and ASA [100 mg/d]) vs
clopidogrel (75 mg/d) and warfarin (INR, 2-2.5; CW).
Patients beneﬁted from a prosthetic graft for above-knee
sites of the distal anastomosis and from a venous graft for
below-knee outﬂow sites. The primary end point was the
5-year bypass patency or primary-assisted patency rate.
The secondary outcome was the occurrence of major
cardiovascular events. Safety outcomes were severe hemor-
rhage (life-threatening, intracerebral, or with hemorrhagic
shock) and moderate bleeding.
Included were 341 patients (173 in the CW group,
168 in the CASA group) from January 2002 to December
2006, with a mean follow-up of 76 months. The 30-day
outcomes in patency rate, hemorrhage, and secondary end
pointswere similar in the twogroups. Conversely, the patency
rates at the 5-year follow-up were 77.3% 6 3.5% in the CW
group and 63.3% 6 4.1% in CASA group (P ¼ .03). The
greatest difference was observed in patients with poor arterial
runoff (CW vs CASA: OR, 3.0; 95% CI, 1.07-8.63 for
freedom for graft failure). The rate of freedom from amputa-
tion was also higher in the CW group (94.2% 6 2.0%)
compared with the CASA group (84.8%6 3.1%; P ¼ .04).
The safety analysis found the incidence rate was similar
in the two groups, at 1.78% patients/year in the CW group
vs 1.62% patients/year in the CASA group (P ¼ .7).
One of the major points of this study was that the
INR was <2 only 9.2% of the time and in the range 86%
of the time
Prosthetic bypass. The BOA study found a signiﬁcant
interactionbetweengraftmaterial and treatment (P¼ .002).10
Therefore, the primary outcome in the prosthetic bypass
subgroup was worse in the VKA group than in the ASA
group (Fig 3).
The Veterans Affairs Cooperative Study11 divided pros-
thetic bypasses into 8-mm-diameter bypasses (161 patients,
typically femorofemoral bypasses) and 6-mm bypasses
(212 patients, typically femoropopliteal and below-knee
bypasses). Overall, there were 44 occlusions (23.5%) of
prosthetic bypasses in the WASA group and 64 occlusions
(34.4%) in the ASA group (P¼ .017; Fig 3). Subgroup anal-
ysis did not show any difference for prosthetic bypasses in
the 8-mm-diameter category, but a statistically signiﬁcant
difference was found for prosthetic bypasses 6 mm in diam-
eter. The lack of patency was 28.6% in the WASA group and
42.1% in ASA group (P ¼ .022). Therefore, the 5-year
patency rates according to the ASA and WASA groups
were, respectively, 47% vs 70% (P ¼ .012) for femoropopli-
teal bypasses and 79% vs 72% (P ¼ .79) for femorofemoral
bypasses. Nevertheless, INR values were signiﬁcantly lower
in patients with occluded bypass (35.4%) than in those with
patent bypasses (30.4%; P ¼ .04).
According to this study, prosthetic femoropopliteal
bypass patency was higher in the WASA group than in
Fig 3. Efﬁcacy and tolerance of antithrombotic drugs reported for prosthetic infrainguinal bypasses. The open boxes are
for occlusion/amputation, and the black boxes are for hemorrhages. Patency was reported at 1 year,a 5 years,b and
2 years,c as originally reported. The relative risk (RR) or hazard ratio (HR) are shown as originally reported when
available, or the RR was calculated from the original data. *Occlusion was reported based on the analysis of primary and
primary assisted patency. ¤Includes death and gastrointestinal (GI), central nervous system (CNS) and genitourinary
(GU) complications.
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of prosthetic bypasses. However, this beneﬁt has to be
balanced by a higher incidence of lethal intracranial hemor-
rhages. Overall, the incidence of major hemorrhage was
signiﬁcantly higher in the WASA group (4.2%) than in
the ASA group (1.6%; P ¼ .02). The beneﬁt/risk ratio
appears to be rather unfavorable for WASA for the 8-mm-
diameter bypass, and on the basis of hemorrhagic complica-
tions, remains questionable for 6-mm-diameter bypass.
In the study by Jackson et al12 regarding ischemic
tolerance after femoropopliteal bypass occlusion, outcomes
for prosthetic bypasses were worse than for autologous vein
bypasses, as the incidence of severe ischemia was 47.7% (ie,
grade$2) vs 18.2% (P ¼ .005), respectively. In a subgroup
analysis of 233 prosthetic femoropopliteal bypasses, occlu-
sions were reported in 67 cases (18 in the WASA group and
47 in the ASA group). Jackson et al12 indicated a tendency
for less severe ischemia in the WASA group (27.8%) than in
the ASA group (55.3%; P ¼ .057). Nevertheless, in the
WASA group, the severity of ischemic tolerance in cases
of occluded prosthetic bypasses was still worse than
for autologous vein bypass occlusion (27.8% vs 18.2%;
P ¼ .49). There was no difference in major amputations af-
ter prosthetic femoropopliteal bypass occlusion in the
WASA group (26%) and in the ASA group (23%;
P ¼ .76). The main limitation of this study was the absence
of safety outcomes, with no report of major hemorrhage.In the subgroup of prosthetic bypasses in the CASPAR
study13 (128 in the CASA group, 125 in the ASA group),
the CASA combination enabled a 35% improvement in the
primary outcome, which was composite criteria of bypass
occlusion, new bypass procedure, major amputation, or
death (HR, 0.65; 95% CI, 0.45-0.95; P ¼ .025). In total,
59 bypass occlusions happened in the ASA group (47%)
compared with 41 (32%) in the CASA group (P ¼ .021;
Fig 3), and 24 major amputations (19.2%) occurred in
the ASA group compared with 12 (9.4%) in the CASA
group (P ¼ .034; Fig 3). The safety analysis for prosthetic
bypasses did not show any statistically signiﬁcant differ-
ences between the groups regarding severe hemorrhage
according to the GUSTO classiﬁcation. In contrast, the
safety analysis showed statistically signiﬁcant differences
between the groups for moderate and minor hemorrhages,
with, respectively, 62 (14.5%) in the CASA group and
25 (5.9%) in the ASA group (P < .01).
RECOMMENDATIONS OF SOCIETIES AND
REVIEW
Antiplatelets Trialists’ Collaboration. In 1994, the
Antiplatelet Trialists’ Collaboration6 published overview
of randomized trials of antiplatelet therapy on the main-
tenance of vascular grafts. Compared with placebo control,
they showed that antiplatelet treatment, mainly aspirin,
dramatically reduced bypass occlusion (864 of 4889
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group; percentage odds reduction, 44%).
European Society of Cardiology. The European
Society of Cardiology15 published recommendations for
antithrombotic therapy after infrainguinal bypass in 2011.
On the basis of an overall positive effect on primary patency
12 months after the procedure, as shown by the Cochrane
meta-analysis,7 the society recommended antiplatelet treat-
ment with aspirin after infrainguinal bypass surgery (Grade
1A). It also suggested antithrombotic treatment with VKA
after autogenous autologous vein bypass (Grade IIbB) and
dual-antiplatelet therapy combining aspirin plus clopidogrel
in case of below-knee prosthetic bypass (Grade IIbB).
Cochrane Collaboration. In 2008, the Cochrane
Collaboration published two systematic reviews on anti-
platelet or antithrombotic agents, respectively, for prevent-
ing thrombosis after infrainguinal arterial bypass surgery.
ASA (or ASA þ dipyridamole) is responsible for a decrease
of bypass occlusion at 12 months (OR, 0.59; 95% CI, 0.45-
0.79), especially in prosthetic grafts (OR, 0.22; 95% CI,
0.12-0.38) but slightly in venous grafts (OR, 0.69; 95%
CI, 0.48-0.99).7 In a second review in 2011 comparing
VKA with aspirin or aspirin and dipyridamole, the
Cochrane Collaboration provided evidence to support a
positive effect of VKA on the patency of venous grafts (OR,
0.65; 95% CI, 0.46-0.92 at 12 months) but not artiﬁcial
grafts. Although the evidence was fair, they concluded that
patients undergoing infrainguinal autologous venous graft
were more likely to beneﬁt from treatment with VKA than
from platelet inhibitors and that patients receiving an arti-
ﬁcial graft beneﬁt from platelet inhibitors (aspirin).16
American College of Chest Physicians. In 2012, the
American College of Chest Physicians17 recommended,
after peripheral arterial bypass surgery, (1) long-term
treatment with aspirin (75 to 100 mg daily) or clopidog-
rel (75 mg/d; Grade 1A) and (2) single-antiplatelet ther-
apy over antiplatelet therapy and warfarin (Grade 1B).
They also suggested (1) aspirin (75-100 mg/d) plus clo-
pidogrel (75 mg/d for 1 year) in patients undergoing
below-knee bypass graft surgery with prosthetic grafts
(Grade 2C), (2) and single-antiplatelet therapy rather than
dual-antiplatelet therapy for all other patients (Grade 2B).
There was no mention regarding warfarin or bypasses at a
high risk of occlusion.
French agency for medical drugs. In June 2012, the
French agency for medical drugs (L’Agence nationale
de sécurité du médicament et des produits de santé
[ANSM]) and the Health Authority18 published a report
on antithrombotic therapy with regard to revascularization
procedure patency, cardiovascular events, and hemorrhagic
complications. The French authorities recommended after
peripheral arterial disease bypasses (1) the use of aspirin as a
single antiplatelet agent, introduced before surgery, for
autologous vein bypass, (2) suggested the combination of
aspirin and VKA for patients with bypass at a high risk of
occlusion, and (3) recommended the use of aspirin as a
single antiplatelet agent introduced before surgery for
prosthetic bypass. The combination of aspirin and VKA wasnot suggested. According to the results of the CASPAR
study, the combination of aspirin and clopidogrel should
be considered for prosthetic bypasses.
As far as the duration of antithrombotic therapy is
concerned, long-term treatment is recommended for
monotherapy, with a regular evaluation of the beneﬁt/
risk ratio recommended for long-term combined aspirin
and VKA treatment.
DISCUSSION
For patients who beneﬁted from vascular bypass
surgery, antiplatelet therapy is useful for secondary preven-
tion of cardiovascular complications and may potentially
prevent bypass occlusion. On the basis of data from the
Antiplatelet Trialists’ and Cochrane meta-analysis,6,7 anti-
platelet agents (mainly aspirin at 75-160 mg/d) improved
the 1-year primary patency of venous or prosthetic infrain-
guinal bypass compared with no speciﬁc treatment. There-
fore, the use of antiplatelet agents became the standard of
care in 2008, and aspirin became the mainstay of treat-
ment. Then, subsequently published studies testing other
antithrombotic drugs or combinations challenged this ther-
apeutic management.
The greatest beneﬁt effect of antiplatelet agents was
observed with prosthetic bypasses.10 The addition of
VKA to ASA increased bypass patency but was associated
with an increased incidence of lethal cranial hemorrhage;
therefore, this combination is not routinely proposed.
The role of aspirin alone remains unclear, but, in such
cases, a double-antiplatelet regimen of clopidogrel and
aspirin for patients who beneﬁted from a below-knee
bypass graft signiﬁcantly improved bypass patency and
the amputation rate, without increasing the incidence of
major hemorrhage. The use of antiplatelet agents was
consensual in all society proposals (Table I). Two
consensus conferences, the European Society of Cardiol-
ogy and the American College of Chest Physicians,15,17
have proposed the dual-antiplatelet therapy at least for
1 year, and this should be considered in clinical practice.
In the case of autologous vein bypasses, several studies,
such as the BOA study,10 and also the Cochrane review,
showed better results for VKA on bypass permeability.
Conversely, the association of VKA with ASA showed no
beneﬁt compared with ASA alone.11 However, analysis of
such studies testing VKA alone or in combination remains
difﬁcult because the INR range used is in disagreement
with our current practice and also because patients were
often subtherapeutic on the target INR. In the BOA study,
the beneﬁt of VKA was balanced by the hemorrhagic risk.
This was probably due to the high INR range (3-4.5) spe-
ciﬁc to this study. In contrast, the Veteran study concluded
that for venous infrainguinal bypass, the beneﬁt/risk ratio
is greater for ASA alone vs WASA.11 Moreover, the analysis
by Jackson et al12 found no difference in lower limb toler-
ance after autologous vein bypass occlusion, regardless of
the allocated antithrombotic regimen. Thus, the authors
concluded that there is no beneﬁt to adding warfarin to
standard ASA therapy for lower limb tolerance when bypass
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might be also the INR range for VKA of 1.4 to 2.8. The
various consensus conferences mainly differ in the partic-
ular case of autologous vein bypass, proposing VKA15,16
or antiplatelet agents.17,18 Clearly, it seems that there is
no beneﬁt of an association of VKA plus ASA, but the
choice between the two drugs, VKA vs ASA, has to be dis-
cussed. The BOA study found no difference between the
two regimens regarding death due to vascular causes,
myocardial infarction, and stroke. This is reinforced by
the results of the WarfarineAspirin Symptomatic Intracra-
nial Disease study showing similar effect of VKA compared
with ASA in secondary prevention regarding ischemic
stroke, myocardial infarction, or death from vascular
causes.19 So if ASA remains the standard of care for patients
who need VKA (for example for atrial ﬁbrillation), it seems
reasonable to use VKA alone rather than VKA plus ASA.
In the particular case of autologous vein infrainguinal
bypasses considered at a high risk for occlusion because of
poor quality vein (ie, a diameter <3 mm), sclerotic vein,
ﬂow back vein, or a vein that is not the great saphenous
vein; or poor arterial run off (ie, anastomosis distal to the distal
third of the leg, feet fed only with collateral arteries, or anasto-
mosis upstream to the stenosis; or iterative bypass), the study
of Sarac et al9 concluded that the combination of warfarin
(INR target 2 to 3) with ASA enables a higher patency rate
and greater limb salvage, with a favorable beneﬁt/risk ratio.
However, the small size of the study is its main weakness.
Similar results were published by Monaco et al14
showing better results of the combination of VKA and an-
tiplatelet agents vs double-antiplatelet agents in patients
with poor arterial runoff. Moreover, the results in this study
were reinforced by the optimal INR follow-up. In the Sarac
et al study, occlusion occurred during the ﬁrst 9 months for
both of the antithrombotic treatment groups considered.
This raises the question of the short duration of dual-
antithrombotic therapy with WASA.
CONCLUSIONS
Revascularization is the optimal treatment for patients
with critical limb ischemia. In such cases, bypass surgery
is often performed in extensive arterial disease, and aspirin
remains the mainstay of treatment to improve infrainguinal
bypass patency in most patients. The greatest beneﬁcial ef-
fect of antiplatelet agents was observed with prosthetic by-
passes. In such cases, the combination of clopidogrel and
aspirin for patients who beneﬁted from a below-knee bypass
graft signiﬁcantly improved bypass patency and the amputa-
tion rate. Antiplatelet regimens had fewer beneﬁcial effects
on autologous vein bypasses. The addition of a VKA is not
routinely proposed because of the increased incidence of
associatedmajor hemorrhage. The use ofVKA alone, instead
of aspirin, probably needs to bediscussed in selected patients,
and the combination of VKA and antiplatelet agents should
be discussed in patients with venous infrainguinal bypasses
considered to be at a high risk for occlusion.
More effort is yet needed to improve bypass graft
patency, and future trials will focus on the developmentof more potent antiplatelet agents or the addition of an
antiplatelet agent with VKA used in an acceptable INR range.
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